Redeye provides an update on Circio and a new base case after the rights issue.
Circio presents a scientific update on the pre-clinical work with the circular RNA platform.
Redeye briefly comments on Circio’s rights issue. We pause our coverage.
Redeye hosts Circio's webcast in which CEO, Dr Erik Digman Wiklund, provides an overview of the latest circVec circular RNA platform in vivo...
As expected, IOVaxis excercised the option to license TG01 in Greater China.
Circio's partner IOVaxis received approval to initiate clinical development of the cancer vaccine TG01 in China on March 1.
Redeye views the waiver of the Finnish loans of EUR6.
Redeye comments on Circio’s partner IOVaxis Therapeutics submission of an application to start a clinical trial with TG01 in China.
Redeye is optimistic about the success of the safety cohort review.
Redeye summarises and comments on Circio’s R&D Webinar on 29 September.
On 29 November, Circio will hold an R&D webinar. In addition to a general corporate and strategy update, the latest pre-clinical data, inclu...
Redeye comments on the third new trial with TG01, which we add to our sum-of-the-parts valuation.
Redeye comments on the improvements made on the circVec platform.
Redeye endorses Circio’s implementation of the cost reduction program, which will extend its runway.
Redeye initiates coverage of Circio (previously Targovax), which has a new focus on circular RNA technology –an area attracting massive inte...
